Medexus Pharmaceuticals Inc. (TSE:MDP) Receives C$5.49 Average Target Price from Brokerages

Shares of Medexus Pharmaceuticals Inc. (TSE:MDP) have earned an average rating of “Buy” from the seven ratings firms that are covering the firm, Marketbeat reports. Two research analysts have rated the stock with a hold rating, one has assigned a buy rating and four have assigned a strong buy rating to the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is C$5.49.

MDP has been the subject of a number of research analyst reports. Alliance Global Partners raised Medexus Pharmaceuticals to a “strong-buy” rating in a research report on Monday, December 23rd. Stifel Nicolaus cut Medexus Pharmaceuticals from a “buy” rating to a “hold” rating and reduced their price objective for the company from C$6.00 to C$3.45 in a research note on Friday, February 7th. Raymond James raised Medexus Pharmaceuticals from an “outperform” rating to a “strong-buy” rating and set a C$4.00 target price on the stock in a research report on Wednesday, January 8th. Stifel Canada downgraded shares of Medexus Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Thursday, February 6th. Finally, Ventum Financial upped their price objective on shares of Medexus Pharmaceuticals from C$5.00 to C$6.25 and gave the stock a “buy” rating in a report on Thursday, January 30th.

Medexus Pharmaceuticals Stock Performance

Shares of MDP stock opened at C$3.09 on Friday. Medexus Pharmaceuticals has a fifty-two week low of C$1.47 and a fifty-two week high of C$5.56. The stock has a 50 day simple moving average of C$3.58 and a two-hundred day simple moving average of C$2.87. The company has a market cap of C$69.18 million, a P/E ratio of 14.78 and a beta of 1.96.

About Medexus Pharmaceuticals

Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.